Catherine A. Schnabel

4.2k total citations
103 papers, 2.8k citations indexed

About

Catherine A. Schnabel is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Catherine A. Schnabel has authored 103 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Cancer Research, 39 papers in Pulmonary and Respiratory Medicine and 39 papers in Oncology. Recurrent topics in Catherine A. Schnabel's work include Breast Cancer Treatment Studies (41 papers), Advanced Breast Cancer Therapies (30 papers) and Estrogen and related hormone effects (26 papers). Catherine A. Schnabel is often cited by papers focused on Breast Cancer Treatment Studies (41 papers), Advanced Breast Cancer Therapies (30 papers) and Estrogen and related hormone effects (26 papers). Catherine A. Schnabel collaborates with scholars based in United States, United Kingdom and Canada. Catherine A. Schnabel's co-authors include Michael L. Cleary, Yakop Jacobs, Mark G. Erlander, Dennis C. Sgroi, Brock E. Schroeder, Mitch Dowsett, Ivana Šestak, Jack Cuzick, Colin E.J. Pritchard and Paul K. Brindle and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Catherine A. Schnabel

97 papers receiving 2.8k citations

Peers

Catherine A. Schnabel

ONCOL

GENET

PRM

Volker Endris Germany

Bo Baldetorp Sweden

Yoon‐La Choi South Korea

Magali Lacroix‐Triki France

Yutaka Yamamoto Japan

Jaana Lahti‐Domenici United States

Paul van Diest Netherlands

Petra van der Groep Netherlands

Nicole Pfarr Germany

Roland Penzel Germany

Volker Endris Germany

Catherine A. Schnabel

1.4k ×1.1

1.2k ×1.0

1.7k ×1.7

ONCOL

288 ×0.5

GENET

1.1k ×1.8

PRM

Citations per year, relative to Catherine A. Schnabel Catherine A. Schnabel (= 1×) peers Volker Endris

Countries citing papers authored by Catherine A. Schnabel

Since Specialization

Citations

This map shows the geographic impact of Catherine A. Schnabel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine A. Schnabel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine A. Schnabel more than expected).

Fields of papers citing papers by Catherine A. Schnabel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine A. Schnabel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine A. Schnabel. The network helps show where Catherine A. Schnabel may publish in the future.

Co-authorship network of co-authors of Catherine A. Schnabel

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine A. Schnabel. A scholar is included among the top collaborators of Catherine A. Schnabel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine A. Schnabel. Catherine A. Schnabel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mamounas, Eleftherios P., Hanna Bandos, Priya Rastogi, et al.. (2024). Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial. Clinical Cancer Research. 30(9). 1984–1991. 7 indexed citations

Foldi, Julia, Anastasia Tsagianni, Max Salganik, et al.. (2023). Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer. BMC Cancer. 23(1). 606–606. 4 indexed citations

Wasan, Harpreet, Jiazhao Wang, Elaine McCartney, et al.. (2023). LBA100 CUP-ONE trial: A prospective double-blind validation of molecular classifiers in the diagnosis of cancer of unknown primary and clinical outcomes. Annals of Oncology. 34. S1339–S1339. 2 indexed citations

Bartlett, John M.S., Dennis C. Sgroi, Kai Treuner, et al.. (2022). Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study. Clinical Cancer Research. 28(9). 1871–1880. 25 indexed citations

Sgroi, Dennis C., Kai Treuner, Yi Zhang, et al.. (2022). Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study. Breast Cancer Research. 24(1). 90–90. 5 indexed citations

Nunes, Raquel, Tal Sella, Kai Treuner, et al.. (2021). Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma. Clinical Cancer Research. 27(20). 5688–5696. 13 indexed citations

Liefers, Gerrit‐Jan, Iris Noordhoek, Dennis C. Sgroi, et al.. (2021). 7P An optimized Breast Cancer Index node-positive (BCIN+) prognostic model for late distant recurrence in patients with hormone receptor-positive (HR+) node-positive breast cancer. Annals of Oncology. 32. S23–S24. 2 indexed citations

Bartlett, John M.S., Ikhlaaq Ahmed, Kai Treuner, et al.. (2021). 11P A Breast Cancer Index (BCI) prognostic model for N0 HR+ breast cancer optimized for late distant recurrence. Annals of Oncology. 32. S25–S25. 1 indexed citations

Noordhoek, Iris, Kai Treuner, Hein Putter, et al.. (2020). Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy. Clinical Cancer Research. 27(1). 311–319. 73 indexed citations

10.

Buus, Richard, Ivana Šestak, Ralf Kronenwett, et al.. (2020). Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. Journal of Clinical Oncology. 39(2). 126–135. 62 indexed citations

11.

Šestak, Ivana, Richard Buus, Jack Cuzick, et al.. (2018). Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer. JAMA Oncology. 4(4). 545–545. 204 indexed citations

12.

Zhang, Yi, Brock E. Schroeder, Piiha-Lotta Jerevall, et al.. (2017). A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes. Clinical Cancer Research. 23(23). 7217–7224. 34 indexed citations

13.

Chapman, Judith‐Anne W., Dennis C. Sgroi, Paul E. Goss, et al.. (2016). Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14. Breast Cancer Research and Treatment. 157(1). 101–108.

14.

Zhang, Yi, Catherine A. Schnabel, Brock E. Schroeder, et al.. (2013). Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence. Clinical Cancer Research. 19(15). 4196–4205. 163 indexed citations

15.

Sgroi, Dennis C., Erin Carney, Elizabeth Zarrella, et al.. (2013). Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker. JNCI Journal of the National Cancer Institute. 105(14). 1036–1042. 153 indexed citations

16.

Kerr, Sarah E., Catherine A. Schnabel, Peggy Sullivan, et al.. (2012). Multisite Validation Study to Determine Performance Characteristics of a 92-Gene Molecular Cancer Classifier. Clinical Cancer Research. 18(14). 3952–3960. 66 indexed citations

17.

Schnabel, Catherine A. & Mark G. Erlander. (2012). Gene expression-based diagnostics for molecular cancer classification of difficult to diagnose tumors. Expert Opinion on Medical Diagnostics. 6(5). 407–419. 6 indexed citations

18.

Weiss, Lawrence M., Peiguo Chu, Brock E. Schroeder, et al.. (2012). Blinded Comparator Study of Immunohistochemical Analysis versus a 92-Gene Cancer Classifier in the Diagnosis of the Primary Site in Metastatic Tumors. Journal of Molecular Diagnostics. 15(2). 263–269. 54 indexed citations

19.

Schnabel, Catherine A., Matthew Wintle, & Orville Kolterman. (2006). Metabolic Effects of the Incretin Mimetic Exenatide in the Treatment of Type 2 Diabetes. SHILAP Revista de lepidopterología. 1 indexed citations

20.

Kasper, Lawryn H., Paul K. Brindle, Catherine A. Schnabel, et al.. (1999). CREB Binding Protein Interacts with Nucleoporin-Specific FG Repeats That Activate Transcription and Mediate NUP98-HOXA9 Oncogenicity. Molecular and Cellular Biology. 19(1). 764–776. 271 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact